Director/PDMR Shareholding

Transaction by Person Discharging Managerial Responsibilities 
Disclosure Rule DTR 3.1.4

On 13 June 2016, the interest of Pascal Soriot, a person discharging managerial responsibilities, in the ordinary shares of AstraZeneca PLC changed as detailed below.

The change in interest relates to the vesting of an award of shares made in June 2013 under the AstraZeneca Performance Share Plan.

Following the application of performance measures specified at the time of grant, Mr Soriot has become beneficially entitled to 78% of the shares originally awarded. In accordance with the plan rules, any unvested part of the award has immediately and irrevocably lapsed.

After sufficient vested shares were withheld to satisfy certain tax obligations arising on the vesting, Mr Soriot has become beneficially entitled to and has received 84,316 shares into a personal brokerage account.

For tax purposes, the fair market value of the shares at vest was 3852 pence per share being the closing price of AstraZeneca ordinary shares on the last trading day preceding the vesting day. 

A C N Kemp
Company Secretary 
14 June 2016 

About Us

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of US $32.8 billion in 2009. For more information please visit:


Documents & Links